The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex works to build markets for new drugs like Casgevy and Journavx.

Vertex Pharmaceuticals (VRTX) reports Q4 earnings today. Investors are eager for updates on new drug launches and growth ...

Fintel reports that on February 12, 2025, Canaccord Genuity upgraded their outlook for Vertex Pharmaceuticals (NasdaqGS:VRTX) from Sell to Hold. Analyst Price Forecast Suggests 10.64% Upside As of ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

The team at Carnegie Museum of Art unpack ‘Palettes of Ambition’, the Ghanaian artist’s monumental artwork conjured from everyday waste ...

Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with common medical procedures.

The Angles were Germanic invaders who came from the Danish-German border and conquered most of Roman Britannia, giving the country its later name, England (Angle land), and dividing it up into ...

After hours: February 12 at 6:22:21 PM EST Loading Chart for A ...